Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis

  • Endler G
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Arterial and venous thromboses, with their clinical manifestations such as stroke, myocardial infarction (MI), or pulmonary embolism, are the major causes of death in developed countries. Several studies in twins and siblings have shown that genetic factors contribute significantly to the development of these diseases. Since the advent of molecular genetics in medicine, it has been a focus of interest to elucidate the role of mutations in various candidate genes and their impact on hemostatic disorders such as arterial and venous thromboses. In this article, we review the current knowledge of the contribution of polymorphisms in coagulation factors to the development of thrombotic diseases. We show that in arterial thrombosis, results are controversial. Only for factor XIII 34Leu a protective effect on the development of myocardial infarction has been demonstrated in several studies. No other single polymorphism in a coagulation factor could be confirmed as a relevant risk factor, although there is evidence for a role of factor V Arg506Gln, factor VII Arg353Gln, and vWF Thr789Ala polymorphisms in patient subgroups. Further studies will be necessary to confirm the value of testing for genetic polymorphisms in arterial thrombosis. A large body of data is available on the role of factor V Arg506Gln and the prothrombin G20210A mutation in venous thrombosis. Some papers already recommend diagnosis and treatment strategies. We will discuss these recent publications on venous thrombosis in our review. 2003 Elsevier Science B.V. All rights reserved

Author-supplied keywords

  • $$Embase
  • $$MI
  • $$Prevalence
  • $$exclude-title-stage-Rachel
  • Austria
  • Cause of Death
  • Death
  • Diagnosis
  • Disease
  • Embolism
  • Factor V
  • Genes
  • Genetic
  • Human
  • Infarction
  • Medical
  • Mutation
  • Myocardial
  • Myocardial Infarction
  • Polymorphism
  • Pregnancy
  • Prothrombin
  • Right
  • Risk
  • Role
  • Stroke
  • Thrombosis
  • University
  • Venous Thrombosis
  • artery thrombosis
  • article
  • blood clotting
  • blood clotting factor 10/ec [Endogenous Compound]
  • blood clotting factor 11/ec [Endogenous Compound]
  • blood clotting factor 12/ec [Endogenous Compound]
  • blood clotting factor 13/ec [Endogenous Compound]
  • blood clotting factor 5/ec [Endogenous Compound]
  • blood clotting factor 7/ec [Endogenous Compound]
  • blood clotting factor 8/ec [Endogenous Compound]
  • blood clotting factor 9/ec [Endogenous Compound]
  • blood clotting factor/ec [Endogenous Compound]
  • developed country
  • disease association
  • disease course
  • fibrinogen/ec [Endogenous Compound]
  • gene
  • gene mutation
  • genetic polymorphism
  • genetic risk
  • genetic variability
  • genetics
  • heart infarction/co [Complication]
  • lung embolism/co [Complication]
  • maternal mortality
  • medical school
  • medicine
  • molecular genetics
  • patient
  • priority journal
  • protein function
  • prothrombin/ec [Endogenous Compound]
  • publication
  • review
  • risk factor
  • vein thrombosis
  • von Willebrand factor/ec [Endogenous Compound]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • G.Mannhalter Endler

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free